This brand name is authorized in United States. It is also authorized in Lithuania.
The drug MYQORZO contains one active pharmaceutical ingredient (API):
1
|
UNII
B1I77MH6K1 - AFICAMTEN
|
|
Aficamten is a reversible allosteric cardiac myosin inhibitor that binds directly to the motor domain of cardiac myosin and prevents it from entering the force-producing state. It is designed to reduce the hypercontractility in the cardiac sarcomere fundamental to the pathophysiology of hypertrophic cardiomyopathy (HCM). The consequent reduction in cardiac contractility reduces left ventricular outflow tract (LVOT) obstruction in HCM patients. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| MYQORZO Film-coated tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| MYQORZO Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| LT | Valstybinė vaistų kontrolės tarnyba | 1106192, 1106193, 1106194, 1106195 |
| US | FDA, National Drug Code | 82112-105, 82112-110, 82112-115, 82112-120 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.